Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

• Drug: AZD5305
• Drug: Enzalutamide
• Drug: Abiraterone Acetate
• Drug: Darolutamide
• Drug: Apalutamide

Inclusion Criteria:

For whole study:

• Age ≥ 18 at the time of screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening.
• Histologically confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of metastatic prostate cancer.
• Candidate for treatment with enzalutamide, abiraterone acetate, darolutamide or apalutamide with documented current evidence of metastatic prostate cancer.
• Surgically or medically castrated.
• Adequate organ and marrow function.
• Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group Performance Status (ECOG PS): 0-1 with no deterioration over the previous 2 weeks.
• Life expectancy ≥ 16 weeks.
• Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to approximately 6 months after the last dosethe amount of medication taken of study treatment .

For Patients Recruited Specifically to tumoura tissue mass that forms from groups of unhealthy cells Pharmacodynamic Cohorts:

• Patients must have at least 1 tumour suitable for paired biopsies

For Part A:

• Patients with Metastatic Castrate ion-Resistant Prostate Cancer (mCRPC) or Metastatic Castration Sensitive Prostate Cancer (mCSPC).

For Part B:

• Patients must have mCSPC (de novo or recurrent) with a baseline PSA value of ≥ 0.2 ng/mL